Atıf Formatları
Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

S. Paydas, "Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity," MEDICAL ONCOLOGY , vol.29, no.3, pp.2159-2165, 2012

Paydas, S. 2012. Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity. MEDICAL ONCOLOGY , vol.29, no.3 , 2159-2165.

Paydas, S., (2012). Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity. MEDICAL ONCOLOGY , vol.29, no.3, 2159-2165.

Paydas, SEMRA. "Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity," MEDICAL ONCOLOGY , vol.29, no.3, 2159-2165, 2012

Paydas, SEMRA. "Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity." MEDICAL ONCOLOGY , vol.29, no.3, pp.2159-2165, 2012

Paydas, S. (2012) . "Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity." MEDICAL ONCOLOGY , vol.29, no.3, pp.2159-2165.

@article{article, author={SEMRA PAYDAŞ}, title={Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity}, journal={MEDICAL ONCOLOGY}, year=2012, pages={2159-2165} }